Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Acquired by Great Point Partners LLC

Great Point Partners LLC increased its holdings in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 232.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 499,152 shares of the company’s stock after acquiring an additional 349,152 shares during the quarter. Great Point Partners LLC owned about 1.16% of Kyverna Therapeutics worth $3,744,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Jennison Associates LLC purchased a new position in Kyverna Therapeutics in the 1st quarter worth approximately $34,743,000. Vanguard Group Inc. purchased a new position in Kyverna Therapeutics during the first quarter worth approximately $6,563,000. StemPoint Capital LP purchased a new position in Kyverna Therapeutics during the first quarter worth approximately $1,018,000. Avoro Capital Advisors LLC acquired a new position in Kyverna Therapeutics during the first quarter worth $11,799,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in Kyverna Therapeutics in the 1st quarter valued at $23,093,000. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on KYTX. HC Wainwright reiterated a “neutral” rating and issued a $7.00 price objective on shares of Kyverna Therapeutics in a report on Thursday, September 19th. JPMorgan Chase & Co. reduced their price target on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Kyverna Therapeutics has an average rating of “Moderate Buy” and an average target price of $34.40.

Kyverna Therapeutics Stock Down 8.5 %

NASDAQ KYTX opened at $5.85 on Tuesday. The stock has a 50-day moving average of $7.82 and a two-hundred day moving average of $13.35. Kyverna Therapeutics, Inc. has a 1-year low of $5.72 and a 1-year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Monday, August 12th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.03. On average, sell-side analysts forecast that Kyverna Therapeutics, Inc. will post -3.38 EPS for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.